EHS
EHS

New Rekovelle analysis shows AMH is robust predictor of ovarian response to fertility treatment

Ferring Pharmaceuticals announced today a new analysis of data from the Phase 3 ESTHER-1 trial showing that natural variations in anti-Müllerian hormone levels during and between a woman’s menstrual cycle have no clinically relevant impact on ovarian response when using AMH to dose Rekovelle for ovarian stimulation.
EHS
Back to top button